dialysis. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: The case group will receive capsule of curcumin 500 mg per 8 hours for six weeks. Intervention 2: The control group will receive placebo 500 mg per 8 hours for six weeks.
Treatment - Drugs
The case group will receive capsule of curcumin 500 mg per 8 hours for six weeks.
The control group will receive placebo 500 mg per 8 hours for six weeks.
Sponsors
Atherosclerosis Research Center of Baqiyatallah University
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: all patients with chronic renal failure undergoing dialysis in dialysis center of Baqiyatallah Hospital exclusion criteria: history of cardiac diseases (due to history taking and non invasive tests); pregnancy and breastfeeding; informed refusal of consent
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left Ventricle Ejection Fraction. Timepoint: Baseline, six weeks after the beginning of the study. Method of measurement: Echocardiography.;Left Ventricle Size. Timepoint: Baseline, six weeks after the beginning of the study. Method of measurement: Echocardiography by measuring volume and diametre of left ventricle. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hb. Timepoint: before intervention. Method of measurement: blood sampling.;PTH. Timepoint: before intervention. Method of measurement: blood sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHesam Sadat Hashemi
Baqiyatallah University of Medical Sciences
Outcome results
None listed